nach oben

Erschienen in:

01.11.2006 | Current Opinion

Cytomegalovirus and Schizophrenia

verfasst von: Dr E. Fuller Torrey, Markus F. Leweke, Markus J. Schwarz, Norbert Mueller, Silke Bachmann, Johannes Schroeder, Faith Dickerson, Robert H. Yolken

Erschienen in: CNS Drugs | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Several lines of evidence suggest that cytomegalovirus (CMV) may play an aetiological role in schizophrenia. Epidemiologically, both have a worldwide distribution and an increased prevalence in lower socioeconomic groups. Studies have reported that some patients experiencing initial episodes of schizophrenia have increased levels of IgG antibodies against CMV, but not other herpes viruses, in their sera and CSF. Treatment with antipsychotic medications may result in a decrease in CMV antibodies, while treatment with anti-herpes virus and anti-inflammatory medications may reduce symptoms in some individuals with schizophrenia. There is also some overlap in the genes that are thought to operate in CMV infections and schizophrenia.

The strongest argument against the role of CMV in schizophrenia is the absence of the traditional CMV neuropathological changes in the brains of individuals with schizophrenia; however, neuropathological studies of CMV have mostly been conducted in immune-compromised individuals.

Further studies on CMV and schizophrenia are needed and may lead to improved treatments for schizophrenia.

Torrey EF. Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr Res 2002 Dec; 58(2–3): 101–15PubMedCrossRef

Torrey EF, Miller J, Rawlings R, et al. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 1997 Nov; 28(1): 1–38PubMedCrossRef

Mortensen PB, Pedersen CB, Westergaard T, et al. Effects of family history and place and season of birth on the risk of schizophrenia. N Engl J Med 1999 Feb; 340(8): 603–8PubMedCrossRef

Harrison G, Gunnell D, Glazebrook C, et al. Association between schizophrenia and social inequality at birth: case-control study. Br J Psychiatry 2001 Oct; 179: 346–50PubMedCrossRef

Hendrick I. Encephalitis lethargica and the interpretation of mental disease. Am J Psychiatry 1928; 7: 989–1014

Goodall E. The exciting cause of certain states of disease, at present classified under “schizophrenia” by psychiatrists, may be infection. J Ment Sci 1932; 78: 746–55

Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis 2003 Nov; 9(11): 1375–80PubMedCrossRef

Yolken RH, Bachmann S, Rouslanova I, et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis 2001 Mar; 32(5): 842–4PubMedCrossRef

Karlsson H, Bachmann S, Schröder J, et al. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci U S A 2001 Apr; 98(8): 4634–9PubMedCrossRef

10.

Hart DJ, Heath RG, Sautter Jr FJ, et al, editor. Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder. Biol Psychiatry 1999 Mar; 45(6): 704–14PubMedCrossRef

11.

Dickerson FB, Boronow JJ, Stallings C, et al. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry 2003 May; 60(5): 466–72PubMedCrossRef

12.

Buka SL, Tsuang MT, Torrey EF, et al. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001 Nov; 58(11): 1032–7PubMedCrossRef

13.

Torrey EF, Yolken RH, Winfrey CJ. Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. Science 1982 May; 216(4548): 892–3PubMedCrossRef

14.

Dauncey K, Giggs J, Baker K, et al. Schizophrenia in Nottingham: lifelong residential mobility of a cohort. Br J Psychiatr 1993; 163: 613–9CrossRef

15.

Griffiths PD, McLaughlin JE. Cytomegalovirus. In: Scheid WM, Whitley RJ, Marra CM, editors. Infections of the central nervous system. 3rd ed. New York: Lippincott, Williams & Wilkins, 2004: 159–173

16.

Scheid WM, Whitley RJ, Marra CM, editors. Infections of the central nervous system. 3rd ed. New York: Lippincott, Williams & Wilkins, 2004

17.

Hanshaw JB. Cytomegalovirus. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. Philadelphia (PA): Saunders, 1976: 127

18.

Torrey EF, Peterson MR. Schizophrenia and the limbic system. Lancet 1974 Oct; II(7886): 942–6CrossRef

19.

Arribas JR, Storch GA, Clifford DB, et al. Cytomegalovirus encephalitis. Ann Intern Med 1996 Oct; 125(7): 577–87PubMed

20.

Torrey EF. Functional psychoses and viral encephalitis. Integr Psychiatry 1986; 4: 224–36

21.

Rothschild DM, O’Grady M, Wecker L. Neonatal cytomegalovirus exposure decreases prepulse inhibition in adult rats: implications for schizophrenia. J Neurosci Res 1999 Aug; 57(4): 429–34PubMedCrossRef

22.

Dickerson F, Kirkpatrick B, Boronow J, et al. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull 2006; 32(2): 396–400PubMedCrossRef

23.

Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995 Jan; 8(1): 131–45PubMed

24.

Srikanth S, Ravi V, Poornima KS, et al. Viral antibodies in recent onset, nonorganic psychoses: correspondence with symptomatic severity. Biol Psychiatry 1994 Oct; 36(8): 517–21PubMedCrossRef

25.

Leweke FM, Gerth CW, Koethe D, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004 Feb; 254(1): 4–8PubMedCrossRef

26.

Albrecht P, Torrey EF, Boone E, et al. Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients. Lancet 1980 Oct; II(8198): 769–72CrossRef

27.

Gotlieb-Stematsky T, Zonis J, Arlazoroff A, et al. Antibodies to Epstein-Barr virus, herpes simplex type 1, cytomegalovirus and measles virus in psychiatric patients. Arch Virol 1981; 67(4): 333–9PubMedCrossRef

28.

Rimón R, Ahokas A, Palo J. Serum and cerebrospinal fluid antibodies to cytomegalovirus in schizophrenia. Acta Psychiatr Scand 1986 Jun; 73(6): 642–4PubMedCrossRef

29.

Shrikhande S, Hirsch SR, Coleman JC, et al. Cytomegalovirus and schizophrenia: a test of a viral hypothesis. Br J Psychiatry 1985 May; 146: 503–6PubMedCrossRef

30.

King DJ, Cooper SJ, Earle JAP, et al. Serum and CSF antibody titres to seven common viruses in schizophrenic patients. Br J Psychiatry 1985 Aug; 147: 145–9PubMedCrossRef

31.

Kaufmann CA, Weinberger DR, Yolken RH, et al. Viruses and schizophrenia. Lancet 1983 (Nov); II(8359): 1136–7CrossRef

32.

van Kammen DP, Mann L, Scheinin M, et al. Spinal fluid monoamine metabolites and anti-cytomegalovirus antibodies and brain scan evaluation in schizophrenia. Psychopharm Bull 1984 Summer; 20(3): 519–22

33.

Moises HW, Rüger R, Reynolds GP, et al. Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient. Eur Arch Psychiatry Neurol Sci 1988; 238(2): 110–3PubMed

34.

C, Torrey EF, Yolken RH. Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr Res 2003 Mar; 60(1): 65–9

35.

Dickerson FB, Boronow JJ, Stallings CR, et al. Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry 2003 Dec; 160(12): 2234–6PubMedCrossRef

36.

Mueller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002 Jun; 159(6): 1029–34CrossRef

37.

Martelius TJ, Wolff H, Bruggeman CA, et al. Induction of cyclo-oxygenase-2 by acute liver allograft rejection and cytomegalovirus infection in the rat. Transpl Int 2002 Dec; 15(12): 610–4PubMedCrossRef

38.

Zhu H, Cong JP, Yu D, et al. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci U S A 2002 Mar; 99(6): 3932–7PubMedCrossRef

39.

Hurme M, Helminen M. Resistance to human cytomegalovirus infection may be influenced by genetic polymorphisms of the tumour necrosis factor-alpha and interleukin-1 receptor antagonist genes. Scand J Infect Dis 1998; 30(5): 447–9PubMedCrossRef

40.

Schwab SG, Mondabon S, Knapp M, et al. Association of tumor necrosis factor alpha gene-G308A polymorphism with schizophrenia. Schizophr Res 2003 Dec; 65(1): 19–25PubMedCrossRef

41.

Boin F, Zanardini R, Pioli R, et al. Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 2001 Jan; 6(1): 79–82PubMedCrossRef

42.

Riedel M, Krönig H, Schwarz MJ. No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 2002 Oct; 252: 232–4PubMedCrossRef

43.

Hurme M, Haanpaa M, Nurmikko T, et al. IL-10 gene polymorphism and herpesvirus infections. J Med Virol 2003; 70Suppl. 1: S48–50PubMedCrossRef

44.

Chiavetto LB, Boin F, Zanardini R, et al. Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol Psychiatry 2002 Mar; 51(6): 480–4CrossRef

45.

Kim JJ, Dayal M, Bacanu S, et al. Exposure to cytomegalovirus and polymorphisms in two genes on chromosome 6p21-23 as joint risk factors for schizophrenia [abstract]. Am J Med Genetics B Neuropsychiatr Genet 2004 Sept; 130B(1): 19

46.

Craighead JE. Cytomegalovirus. In: Pathology and pathogenesis of human viral disease. San Diego (CA): Academic Press, 2000: 87–115

47.

Bailey OT, Wolf A, Schneck SA, et al. Iatrogenic modification of tissue responses to infectious agents in the central nervous system. Res Publ Assoc Res Nerv Ment Dis 1968; 44: 445–62PubMed

48.

Dorfman LJ. Cytomegalovirus encephalitis in adults. Neurology 1973 Feb; 23(2): 136–44PubMedCrossRef

49.

Reuter JD, Gomez DL, Wilson JH, et al. Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain. J Virol 2004 Feb; 78(3): 1473–87PubMedCrossRef

Titel: Cytomegalovirus and Schizophrenia
verfasst von: Dr E. Fuller Torrey
Markus F. Leweke
Markus J. Schwarz
Norbert Mueller
Silke Bachmann
Johannes Schroeder
Faith Dickerson
Robert H. Yolken
Publikationsdatum: 01.11.2006
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 11/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200620110-00001

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2006

Varenicline

A Naturalistic Study of Galantamine for Alzheimer’s Disease

Epilepsy with Myoclonic Absences

Spotlight on Eletriptan in Migraine

Psychiatric Manifestations of Graves’ Hyperthyroidism